LON:MPH Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free MPH Stock Alerts GBX 26.50 -0.50 (-1.85%) (As of 12/17/2020) Add Compare Share Share Today's Range 26▼ 26.5050-Day Range 26.50▼ 26.5052-Week Range 13▼ 60Volume49,264 shsAverage Volume333,975 shsMarket Capitalization£89.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Mereo BioPharma Group plc (MPH.L) alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Mereo BioPharma Group plc (MPH.L) Stock (LON:MPH)Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.Read More MPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MPH Stock News HeadlinesApril 18, 2024 | americanbankingnews.comMereo BioPharma Group plc (MPH.L) (LON:MPH) Stock Passes Below Fifty Day Moving Average of $26.50April 14, 2024 | morningstar.comMereo BioPharma Group PLC ADR MREOApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinFebruary 24, 2024 | msn.comMereo BioPharma Group plc - Depositary Receipt () (MREO) Price Target Increased by 17.65% to 5.10February 23, 2024 | benzinga.comMereo BioPharma Group Stock (NASDAQ:MREO), Insider Trading ActivityFebruary 22, 2024 | wsj.comMereo BioPharma Group PLC ADRJanuary 8, 2024 | msn.comMereo BioPharma provides update on pipeline progress, reaffirms cash runway guidanceJanuary 8, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)April 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinJanuary 8, 2024 | markets.businessinsider.comMereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsDecember 13, 2023 | seekingalpha.comMereo BioPharma: Lagging Stock Despite Positive DataOctober 23, 2023 | markets.businessinsider.comMereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateJune 14, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for Mereo Biopharma Group Plc (MREO)June 6, 2023 | msn.comUltragenyx, Mereo shares gain after positive results from study of bone disorder treatmentJune 6, 2023 | msn.comUltragenyx, Mereo gain on Phase 2 data for bone disorder therapyMay 31, 2023 | technews.tmcnet.comMereo BioPharma to Present at the Jefferies Healthcare ConferenceMay 29, 2023 | msn.comNavigating Mereo BioPharma's Future: Risky Proposition Despite Strides In Rare Disease TreatmentMay 5, 2023 | msn.comMereo BioPharma transfers ADS listing from Nasdaq Global Market to Nasdaq Capital MarketMay 5, 2023 | technews.tmcnet.comMereo BioPharma Announces Listing Transfer to Nasdaq Capital MarketMarch 28, 2023 | benzinga.comMereo BioPharma Reports Full Year 2022 Financial Results and Recent HighlightsMarch 21, 2023 | msn.comMereo soars ~25% after FDA, EMA guidance on main goals of trial for lung disease drugDecember 21, 2022 | benzinga.comShort Volatility Alert: Mereo BiopharmaOctober 28, 2022 | technews.tmcnet.comMereo BioPharma Reaches Cooperation Agreement with Rubric Capital ManagementOctober 17, 2022 | marketwatch.comMereo BioPharma Gets FDA Fast-Track Designation for Alvelestat >MREOOctober 17, 2022 | markets.businessinsider.comMereo BioPharma: FDA Grants Fast Track Designation For Alvelestat - Quick FactsOctober 5, 2022 | marketwatch.comRubric Capital Management Increases Slate of Proposed Mereo BioPharmaDirector Nominees to FiveSeptember 26, 2022 | benzinga.comMereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the BoardSee More Headlines Receive MPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/29/2020Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:MPH CUSIPN/A CIKN/A Webmereobiopharma.com Phone44 33 3023 7300FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio164.26 Current Ratio2.98 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 17.12 per share Price / Cash Flow1.55 Book ValueGBX 7.20 per share Price / Book3.68Miscellaneous Outstanding Shares338,713,984Free FloatN/AMarket Cap£89.76 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Denise Scots-Knight (Age 61)Co-Founder, CEO & Exec. Director Comp: $751.37kMr. Charles Sermon (Age 51)Co-Founder, Gen. Counsel & Company Sec. Comp: $545.68kDr. Alastair MacKinnon (Age 50)Co-Founder & Chief Medical Officer Comp: $540.12kMr. John Richard (Age 63)Co-Founder & Head of Corp. Devel. Comp: $512.99kMr. Michael Stephen Wyzga MBA (Age 65)Interim CFO & Exec. Director Comp: $27.59kMs. Alexandra Hughes-Wilson (Age 49)Head of Patient Access & Commercial Planning Comp: $265.93kMs. Jill Henrich (Age 57)US Site Head & Sr. VP of Regulatory Affairs Comp: $286.93kDr. John A. Lewicki (Age 68)Chief Scientific Officer Dr. Fiona BorHead of Intellectual PropertyMr. Ian HodgsonHead of Clinical OperationsMore ExecutivesKey CompetitorsScancellLON:SCLPFaron Pharmaceuticals OyLON:FARNFutura MedicalLON:FUMVerseonLON:VSNOpen OrphanLON:ORPHView All Competitors MPH Stock Analysis - Frequently Asked Questions How have MPH shares performed in 2024? Mereo BioPharma Group plc (MPH.L)'s stock was trading at GBX 26.50 on January 1st, 2024. Since then, MPH shares have increased by 0.0% and is now trading at GBX 26.50. View the best growth stocks for 2024 here. How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter? Mereo BioPharma Group plc (MPH.L) (LON:MPH) announced its quarterly earnings results on Tuesday, September, 29th. The company reported ($105.00) EPS for the quarter. What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA), Amgen (AMGN), ARMOUR Residential REIT (ARR), Arena Pharmaceuticals (ARNA) and Ardelyx (ARDX). How do I buy shares of Mereo BioPharma Group plc (MPH.L)? Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:MPH) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc (MPH.L) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
